APYX

Apyx is a small-cap surgical-aesthetics company (Renuvion, the new FDA-cleared AYON body-contouring system, J-Plasma) whose story is a not-yet-proven turnaround. The good news is real: FY2025 revenue grew 9.9% to $52.8M — its best level in the five-year history — while the net loss narrowed 52% to -$11.2M and the operating loss shrank 66% to -$6.45M. Gross margin of 62.5% is genuinely strong for a device maker, and management's November 2024 restructuring (a ~25% U.S. headcount cut, eliminated bonuses, a slimmed board) is credited with ~$4.3M of annualized savings that are visibly flowing through the P&L. So the trajectory is improving.

But the base is weak and the balance sheet is stretched. This is the fifth consecutive annual net loss (2021–2025 losses: -$15.2M, -$23.2M, -$18.7M, -$23.5M, -$11.2M) and a -$89.1M accumulated deficit that deepened another 14% this year. Operating cash flow was -$8.0M against just $31.7M of cash, i.e. roughly four years of runway before financing — and management explicitly says it may fund the gap 'through additional equity and/or debt financing,' warning of dilution and that it may have to 'delay, limit, reduce, or terminate' sales, marketing and product development if capital isn't available. Dilution is already underway: shares rose 10.7% YoY. Leverage is high — $34.8M long-term debt exceeds $14.5M of equity (liabilities/equity 3.58x), so the ROE of -77% flatters nothing. Tellingly, R&D was cut 33.6% to $3.37M, which trims losses today at the possible cost of the product pipeline.